The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease in industrialized countries. NAFLD progresses through the inflammatory phase of non-alcoholic steatohepatitis (NASH) to fibrosis and cirrhosis, with some cases developing liver failure or hepatocellular carcinoma (HCC). Liver biopsy remains the gold standard approach to a definitive diagnosis of NAFLD and the distinction between simple steatosis and NASH. The pathogenesis of NASH is still not clear. Several theories have been proposed ranging from the "Two Hit Theory" to the "Multiple Hit Theory". However, the general consensus is that the gut microbiota, oxidative stress, and mitochondrial damage play key roles in the pathogenesis of NASH. The interaction between the gut epithelia and some commensal bacteria induces the rapid generation of reactive oxygen species (ROS). The main goal of any therapy addressing NASH is to reverse or prevent progression to liver fibrosis/cirrhosis. This problem represents the first "Achilles' heel" of the new molecules being evaluated in most ongoing clinical trials. The second is the inability of these molecules to reach the mitochondria, the primary sites of energy production and ROS generation. Recently, a variety of non-pharmacological and pharmacological treatment approaches for NASH have been evaluated including vitamin E, the thiazolidinediones, and novel molecules related to NASH pathogenesis (including obeticholic acid and elafibranor). Recently, a new isoform of human manganese superoxide dismutase (MnSOD) was isolated and obtained in a synthetic recombinant form designated rMnSOD. This protein has been shown to be a powerful antioxidant capable of mediating ROS dismutation, penetrating biological barriers via its uncleaved leader peptide, and reducing portal hypertension and fibrosis in rats affected by liver cirrhosis. Based on these distinctive characteristics, it can be hypothesized that this novel recombinant protein (rMnSOD) potentially represents a new and highly efficient adjuvant therapy to counteract the progression from NASH to HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Mitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein
Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., & Mathison, J. C. (1990) · Science · doi:10.1126/science.1698311 · Cited by 3,987
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals
Ohsawa, I., Ishikawa, M., Takahashi, K., Watanabe, M., Nishimaki, K., Yamagata, K., Katsura, K.-I., Katayama, Y., Asoh, S., & Ohta, S. (2007) · Nature Medicine · doi:10.1038/nm1577 · Cited by 2,560
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., & de Lédinghen, V. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.018 · Cited by 2,487
Fiber and prebiotics: Mechanisms and health benefits
Slavin, J. (2013) · Nutrients · doi:10.3390/nu5041417 · Cited by 2,340 · cited 1×
“In fact, prebiotics such as high-fiber foods, are consumed by and help the endogenous gut bacteria to survive and contribute to the maintenance of the general welfare of the organism [103].”
BackgroundMittler, R., Vanderauwera, S., Suzuki, N., Miller, G., Tognetti, V. B., Vandepoele, K., Gollery, M., Shulaev, V., & Van Breusegem, F. (2011) · Trends in Plant Science · doi:10.1016/j.tplants.2011.03.007 · Cited by 2,305
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S. (2007) · Hepatology · doi:10.1002/hep.21669 · Cited by 2,077
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“The transcription of PPARG Coactivator 1 Alpha (PPARGC1A) is the most important regulator of mitochondrial biogenesis [76,77] and is involved in hepatic glucogenesis [78].”
BackgroundKlein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network
Scarpulla, R. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.09.019 · Cited by 1,281
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005) · Hepatology · doi:10.1002/hep.20734 · Cited by 1,263
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
The role of the gut microbiota in energy metabolism and metabolic disease
Cani, P., & Delzenne, N. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168164 · Cited by 974
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“Pruritus has been reported as a reversible sideeffect of treatment with this molecule, in addition to the emergence of cardiovascular events [143,144].”
BackgroundLi, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
The weight of leptin in immunity
Cava, A. L., & Matarese, G. (2004) · Nature Reviews Immunology · doi:10.1038/nri1350 · Cited by 927
Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut
Collins, M. D., & Gibson, G. R. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.5.1052s · Cited by 912
Brun, P., Castagliuolo, I., Leo, V. D., Buda, A., Pinzani, M., Palù, G., & Martines, D. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2006 · Cited by 864
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes
Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B., & Tilg, H. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.145 · Cited by 819
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Pagano, G., Pacini, G., Musso, G., Gambino, R., Mecca, F., Depetris, N., Cassader, M., David, E., Cavallo-Perin, P., & Rizzetto, M. (2002) · Hepatology · doi:10.1053/jhep.2002.30690 · Cited by 753
Wong, R. J., Cheung, R., & Ahmed, A. (2014) · Hepatology · doi:10.1002/hep.26986 · Cited by 723
Non alcoholic fatty liver disease and metabolic syndrome.
Paschos, P., & Paletas, K. (2009) · PubMed · Cited by 718
Part 1: The Human Gut Microbiome in Health and Disease.
Bull, M. J., & Plummer, N. T. (2014) · PubMed · Cited by 698
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Paik, Y.-H., Schwabe, R. F., Bataller, R., Russo, M. P., Jobin, C., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50182 · Cited by 651
Liu, Q., Duan, Z. P., Ha, D. K., Bengmark, S., Kurtovic, J., & Riordan, S. M. (2004) · Hepatology · doi:10.1002/hep.20194 · Cited by 638
The epidemiology of non‐alcoholic fatty liver disease
Bellentani, S. (2017) · Liver International · doi:10.1111/liv.13299 · Cited by 606
How we detect microbes and respond to them: the Toll-like receptors and their transducers
Beutler, B., Hoebe, K., Du, X., & Ulevitch, R. J. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0203082 · Cited by 591
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
Argo, C. K., Northup, P. G., Al-Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.019 · Cited by 552
Intestinal luminal nitrogen metabolism: Role of the gut microbiota and consequences for the host
Davila, A.-M., Blachier, F., Gotteland, M., Andriamihaja, M., Benetti, P.-H., Sanz, Y., & Tomé, D. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.005 · Cited by 548 · cited 1×
“This discovery may lead to the identification and commercialization of probiotics that replenish glycine and/or increase glutathione in the gut [82].”
BackgroundSanyal, A. J., Banas, C., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Heuman, D., Coterrell, A., Fisher, R. A., et al. (2006) · Hepatology · doi:10.1002/hep.21103 · Cited by 522
Seki, S., Kitada, T., Yamada, T., Sakaguchi, H., Nakatani, K., & Wakasa, K. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00073-9 · Cited by 521
Ertle, J., Dechêne, A., Sowa, J., Penndorf, V., Herzer, K., Kaiser, G., Schlaak, J. F., Gerken, G., Syn, W., & Canbay, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25797 · Cited by 518
An update on the use and investigation of probiotics in health and disease
Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., Sherman, P. M., & Mayer, E. A. (2013) · Gut · doi:10.1136/gutjnl-2012-302504 · Cited by 503 · cited 1×
“Probiotics were defined by the World Health Organization in 2001 as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” [101,102].”
BackgroundLipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation
Su, G. L. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00550.2001 · Cited by 480
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Linking endothelial dysfunction with endothelial cell activation
Liao, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66843 · Cited by 456
Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases
Loguercio, C., Federico, A., Tuccillo, C., Terracciano, F., D'Auria, M. V., De Simone, C., & Blanco, C. D. V. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000165671.25272.0f · Cited by 449
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
Enterocyte TLR4 Mediates Phagocytosis and Translocation of Bacteria Across the Intestinal Barrier
Neal, M. D., Leaphart, C., Levy, R., Prince, J., Billiar, T. R., Watkins, S., Li, J., Cetin, S., Ford, H., Schreiber, A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.3070 · Cited by 433
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future†
Wieckowska, A., McCullough, A. J., & Feldstein, A. E. (2007) · Hepatology · doi:10.1002/hep.21768 · Cited by 423
Ma, X., Hua, J., & Li, Z. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.05.025 · Cited by 415
The gut microbiota modulates host amino acid and glutathione metabolism in mice
Mardinoglu, A., Shoaie, S., Bergentall, M., Ghaffari, P., Zhang, C., Larsson, E., Bäckhed, F., & Nielsen, J. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156487 · Cited by 383
Land, W., Schneeberger, H., Schleibner, S., Illner, W.-D., Abendroth, D., Rutili, G., Arfors, K. E., & Messmer, K. (1994) · Transplantation · doi:10.1097/00007890-199401001-00010 · Cited by 377
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 376
Excess Risk of Primary Liver Cancer in Patients With Diabetes Mellitus
Adami, H.-O., Chow, W.-H., Nyren, O., Berne, C., Linet, M. S., Ekbom, A., Wolk, A., McLaughlin, J. K., & Fraumeni, J. F. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1472 · Cited by 373
Acetaldehyde adducts in alcoholic liver disease
Setshedi, M., Wands, J. R., & de la Monte, S. M. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.3.12288 · Cited by 365
Role of Mitochondria in Nonalcoholic Fatty Liver Disease
Nassir, F., & Ibdah, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058713 · Cited by 364
Nelson, J. E., Wilson, L., Brunt, E. M., Yeh, M. M., Kleiner, D. E., Unalp-Arida, A., & Kowdley, K. V. (2011) · Hepatology · doi:10.1002/hep.24038 · Cited by 356
Non-Alcoholic Fatty Liver Disease and the Metabolic Syndrome
Najjar, S. M. (2011) · Metabolic Basis of Obesity · doi:10.1007/978-1-4419-1607-5_12 · Cited by 354
Nonalcoholic fatty liver disease: A review of current understanding and future impact
Charlton, M. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00440-9 · Cited by 350
SOD, oxidative stress and human pathologies: a brief history and a future vision
McCord, J. M., & Edeas, M. A. (2005) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2005.03.005 · Cited by 347
Seki, S., Habu, Y., Kawamura, T., Takeda, K., Dobashi, H., Ohkawa, T., & Hiraide, H. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017404.x · Cited by 343
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Cui, J., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 326
Purohit, V., Bode, J. C., Bode, C., Brenner, D. A., Choudhry, M. A., Hamilton, F., Kang, Y. J., Keshavarzian, A., Rao, R., Sartor, R. B., et al. (2008) · Alcohol · doi:10.1016/j.alcohol.2008.03.131 · Cited by 325
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Polyzos, S. A., Toulis, K. A., Goulis, D. G., Zavos, C., & Kountouras, J. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.003 · Cited by 311
Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., Carreras, M. C., Poderoso, J. J., & Gores, G. J. (2015) · Liver International · doi:10.1111/liv.12570 · Cited by 294
Multiple glutathione disulfide removal pathways mediate cytosolic redox homeostasis
Morgan, B., Ezeriņa, D., Amoako, T. N. E., Riemer, J., Seedorf, M., & Dick, T. P. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1142 · Cited by 288
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284
Involvement of free radicals and oxidative stress in NAFLD/NASH
Sumida, Y., Niki, E., Naito, Y., & Yoshikawa, T. (2013) · Free Radical Research · doi:10.3109/10715762.2013.837577 · Cited by 280 · cited 2×
“Until recently, hepatic steatosis [22] and oxidative stress [23] – the latter also caused by changes in the gut microbiota [24,25] – were seen”
BackgroundSafadi, R., Konikoff, F. M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., Safadi, R., Konikoff, F. M., Hershkovitz, A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.038 · Cited by 274
Antioxidants: The Basics-what they are and how to Evaluate them
Halliwell, B. (1996) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60976-x · Cited by 270
Guerra Ruiz, A., Casafont, F., Crespo, J., Cayón, A., Mayorga, M., Estebanez, A., Fernadez-Escalante, J. C., & Pons-Romero, F. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9243-7 · Cited by 269
Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy
Bajaj, J. S., Saeian, K., Christensen, K. M., Hafeezullah, M., Varma, R. R., Franco, J., Pleuss, J. A., Krakower, G., Hoffmann, R. G., & Binion, D. G. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01861.x · Cited by 269
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., & Szabo, G. (2009) · Hepatology · doi:10.1002/hep.22711 · Cited by 263
The role of fatty acids in the development and progression of nonalcoholic fatty liver disease
Gentile, C. L., & Pagliassotti, M. J. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.10.001 · Cited by 252
Kim, J. J., & Sears, D. D. (2010) · Gastroenterology Research and Practice · doi:10.1155/2010/212563 · Cited by 248
Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver
Gustot, T., Lemmers, A., Moreno, C., Nagy, N., Quertinmont, E., Nicaise, C., Franchimont, D., Louis, H., Devière, J., & Le Moine, O. (2006) · Hepatology · doi:10.1002/hep.21138 · Cited by 244
Preiss-Landl, K., Zimmermann, R., Hämmerle, G., & Zechner, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200210000-00002 · Cited by 240
Therapies in non‐alcoholic steatohepatitis (NASH)
Oseini, A. M., & Sanyal, A. J. (2017) · Liver International · doi:10.1111/liv.13302 · Cited by 235
Mechanism of the tumor suppressive effect of MnSOD overexpression
Oberley, L. W. (2005) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2005.03.006 · Cited by 232
Chang, Y., Ryu, S., Sung, E., & Jang, Y. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081257 · Cited by 229
Albano, E., Mottaran, E., Vidali, M., Reale, E., Saksena, S., Occhino, G., Burt, A. D., & Day, C. P. (2005) · Gut · doi:10.1136/gut.2004.057968 · Cited by 219
Agrawal, A., Sharma, B. C., Sharma, P., & Sarin, S. K. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.113 · Cited by 216
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
Weston, C. J., Shepherd, E. L., Claridge, L. C., Rantakari, P., Curbishley, S. M., Tomlinson, J. W., Hubscher, S. G., Reynolds, G. M., Aalto, K., Anstee, Q. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73722 · Cited by 214
Molecular Structure and Organization of the Human Manganese Superoxide Dismutase Gene
WAN, X. S., DEVALARAJA, M. N., & ST. CLAIR, D. K. (1994) · DNA and Cell Biology · doi:10.1089/dna.1994.13.1127 · Cited by 213
Rao, A., Kosters, A., Mells, J. E., Zhang, W., Setchell, K. D. R., Amanso, A. M., Wynn, G. M., Xu, T., Keller, B. T., Yin, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4823 · Cited by 211
Impact of oestrogens on the progression of liver disease
Shimizu, I. (2003) · Liver International · doi:10.1034/j.1600-0676.2003.00811.x · Cited by 207
Lipopolysaccharide (LPS)-Binding Protein Mediates LPS Detoxification by Chylomicrons
Vreugdenhil, A. C. E., Rousseau, C. H., Hartung, T., Greve, J. W. M., van ‘t Veer, C., & Buurman, W. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1399 · Cited by 206
Immunological functions of leptin and adiponectin
Carbone, F., La Rocca, C., & Matarese, G. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.018 · Cited by 204
Redox signaling mediated by the gut microbiota
Jones, R. M., & Neish, A. S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.10.495 · Cited by 202
Sokol, R. J., McKim, J. M., Goff, M. C., Ruyle, S. Z., Devereaux, M. W., Han, D., Packer, L., & Everson, G. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70644-4 · Cited by 199
Friedman, S., Sanyal, A., Goodman, Z., Lefebvre, E., Gottwald, M., Fischer, L., & Ratziu, V. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.02.012 · Cited by 197
Manganese superoxide dismutase regulation and cancer
Dhar, S. K., & St. Clair, D. K. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.009 · Cited by 196
Synthesis and processing of the precursor for human mangano-superoxide dismutase
Wispe', J. R., Clark, J. C., Burhans, M. S., Kropp, K. E., Korfhagen, T. R., & Whitsett, J. A. (1989) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(89)90058-7 · Cited by 196
Non‐alcoholic fatty liver disease from pathogenesis to management: an update
Musso, G., Gambino, R., & Cassader, M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00657.x · Cited by 196
Unraveling the multiple roles of leptin in inflammation and autoimmunity
La Cava, A., Alviggi, C., & Matarese, G. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0492-1 · Cited by 193
Sanyal, D., Mukherjee, P., Raychaudhuri, M., Ghosh, S. K., Mukherjee, S., & Chowdhury, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163172 · Cited by 184
FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
Wu, X., Ge, H., Lemon, B., Vonderfecht, S., Weiszmann, J., Hecht, R., Gupte, J., Hager, T., Wang, Z., Lindberg, R., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.068783 · Cited by 183
Kojer, K., Bien, M., Gangel, H., Morgan, B., Dick, T. P., & Riemer, J. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.165 · Cited by 179
Harrison, S. A., Marri, S. R., Chalasani, N., Kohli, R., Aronstein, W., Thompson, G. A., Irish, W., Miles, M. V., Xanthakos, S. A., Lawitz, E., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13816 · Cited by 176
Nanomedicine for Cancer: Lipid-Based Nanostructures for Drug Delivery and Monitoring
Namiki, Y., Fuchigami, T., Tada, N., Kawamura, R., Matsunuma, S., Kitamoto, Y., & Nakagawa, M. (2011) · Accounts of Chemical Research · doi:10.1021/ar200011r · Cited by 168
Aharoni-Simon, M., Hahn-Obercyger, M., Pen, S., Madar, Z., & Tirosh, O. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.55 · Cited by 167
Gracia‐Sancho, J., Laviña, B., Rodríguez-Vilarrupla, A., García‐Calderó, H., Fernández, M., Bosch, J., & García‐Pagán, J. C. (2008) · Hepatology · doi:10.1002/hep.22166 · Cited by 162
Folz, R. J., Guan, J., Seldin, M. F., Oury, T. D., Enghild, J. J., & Crapo, J. D. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.17.4.2826 · Cited by 160
Gut microbiota and host metabolism in liver cirrhosis
Usami, M., Miyoshi, M., & Yamashita, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11597 · Cited by 158
The hyperdynamic circulation in cirrhosis
Blendis, L. M., & Wong, F. S.-H. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00124-3 · Cited by 154
Brun, P., Castagliuolo, I., Pinzani, M., Palù, G., & Martines, D. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00537.2004 · Cited by 147
Probiotics and gut health: A special focus on liver diseases
Gratz, S. W., Mykkanen, H., & El-Nezami, H. S. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i4.403 · Cited by 145
Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis
Ricci, C., Pastukh, V. M., Leonard, J. N., Turrens, J. F., Wilson, G. L., Schaffer, D., & Schaffer, S. W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00362.2007 · Cited by 145
Weydert, C. J. D., Roling, B., Liu, J., Hinkhouse, M. M., Ritchie, J. M., Oberley, L. W., & Cullen, J. J. (2003) · PubMed · Cited by 145
Miethke, A. G., Zhang, W., Simmons, J., Taylor, A. E., Shi, T., Shanmukhappa, S. K., Karns, R., White, S., Jegga, A. G., Lages, C. S., et al. (2016) · Hepatology · doi:10.1002/hep.27973 · Cited by 141
Nonalcoholic fatty liver disease and cardiovascular risk
Misra, V. L., Khashab, M. A., & Chalasani, N. (2009) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0008-4 · Cited by 140
Wettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 140
Probiotics for patients with hepatic encephalopathy
McGee, R., Bakens, A., Wiley, K. E., Riordan, S. M., & Webster, A. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008716.pub2 · Cited by 135
Review article: role of oxidative stress in the progression of non‐alcoholic steatosis
Albano, E., Mottaran, E., Occhino, G., Reale, E., & Vidali, M. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02601.x · Cited by 134
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
Doulberis, M., Kotronis, G., Gialamprinou, D., Kountouras, J., & Katsinelos, P. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.013 · Cited by 128
Malaguarnera, M., Gargante, M. P., Malaguarnera, G., Salmeri, M., Mastrojeni, S., Rampello, L., Pennisi, G., Volti, G. L., & Galvano, F. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328330a8d3 · Cited by 120
Usami, M., Miyoshi, M., Kanbara, Y., Aoyama, M., Sakaki, H., Shuno, K., Hirata, K., Takahashi, M. P., Ueno, K., Tabata, S., et al. (2011) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607110379813 · Cited by 114
Clementi, A. H., Gaudy, A. M., van Rooijen, N., Pierce, R. H., & Mooney, R. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.007 · Cited by 103
Dong, J. Q., Rossulek, M. I., Somayaji, V. R., Baltrukonis, D. J., Liang, Y., Hudson, K. J., Hernandez‐Illas, M., & Calle, R. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12676 · Cited by 101
Nanoparticles for intracellular-targeted drug delivery
Paulo, C., das Neves, R. P., & Ferreira, L. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/49/494002 · Cited by 101
Review article: probiotics in gastrointestinal and liver diseases
Jonkers, D. M. A. E., & Stockbrügger, R. W. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03480.x · Cited by 100
Nonalcoholic fatty liver disease: new treatments
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 98
Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management
Portincasa, P., Grattagliano, I., Palmieri, V. O., & Palasciano, G. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.10.014 · Cited by 89
Immunomodulation by Gut Microbiota: Role of Toll-Like Receptor Expressed by T Cells
Valentini, M., Piermattei, A., Sante, G. D., Migliara, G., Delogu, G., & Ria, F. (2014) · Journal of Immunology Research · doi:10.1155/2014/586939 · Cited by 86
Gupta, N. R., Kumar, A., Sharma, P., Garg, V., Sharma, B. C., & Sarin, S. K. (2013) · Liver International · doi:10.1111/liv.12172 · Cited by 85
Hepatic estrogen receptor in human liver disease
Porter, L. E., Elm, M. S., Thiel, D. H. V., et al. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90026-6 · Cited by 83
FILOZOF, C. M., Goldstein, B. J., Williams, R. N., & Sanyal, A. J. (2015) · Drugs · doi:10.1007/s40265-015-0437-3 · Cited by 79
Ma, H., Gómez, V., Lu, L., Yang, X.-J., Wu, X., & Xiao, S. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05548.x · Cited by 78
Guillaume, M., Rodrı́guez-Vilarrupla, A., Gracia‐Sancho, J., Rosado, E., Mancini, A., Bosch, J., & García‐Pagán, J. C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.010 · Cited by 75
Self-citationMolavi, B., Rassouli, N., Bagwe, S., & Rasouli, N. (2007) · PubMed Central · Cited by 72
The Impact of Bariatric Surgery on Nonalcoholic Steatohepatitis
Rabl, C., & Campos, G. M. (2012) · Seminars in liver disease (Print) · doi:10.1055/s-0032-1306428 · Cited by 72
Estrogen Signalling and the Metabolic Syndrome: Targeting the Hepatic Estrogen Receptor Alpha Action
Matic, M., Bryzgalova, G., Gao, H., Antonson, P., Humire, P., Omoto, Y., Portwood, N., Pramfalk, C., Efendić, S., Berggren, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057458 · Cited by 72
Wang, Y., Ghoshal, S., Ward, M. R., de Villiers, W. J. S., Woodward, J. G., & Eckhardt, E. R. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008442 · Cited by 70
Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study
Tandon, P., Moncrief, K., Madsen, K., Arrieta, M., Owen, R. J., Bain, V. G., Wong, W., & Ma, M. M. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02020.x · Cited by 69
Antioxidant Therapy in Nonalcoholic Steatohepatitis
Al‐Busafi, S. A., Bhat, M., Wong, P. Y. N., Ghali, P., & Deschênes, M. (2012) · Hepatitis Research and Treatment · doi:10.1155/2012/947575 · Cited by 66
Compartment-dependent management of H2O2 by peroxisomes
Fritz, R., Bol, J., Hebling, U., Angermüller, S., Völkl, A., Fahimi, H. D., & Mueller, S. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.01.014 · Cited by 65
Lin, J. H., Zhang, J. J., Lin, S., & Chertow, G. M. (2014) · The Nephron journals/Nephron journals · doi:10.1159/000369152 · Cited by 64
Chagas, A. L., Kikuchi, L., de Oliveira, C. P. M. S., Paranaguá‐Vezozzo, D. C., de Mello, E. S., de Oliveira, A. C. S., Cella, L. C., Herman, P., Bacchella, T., Caldwell, S. H., et al. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009005000019 · Cited by 64
Managing nonalcoholic fatty liver disease: recommendations for family physicians.
Grattagliano, I., Portincasa, P., Palmieri, V. O., & Palasciano, G. (2007) · PubMed · Cited by 64
Jani, R. H., Kansagra, K., Jain, M. R., & Patel, H. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0128-3 · Cited by 62
Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration
Schilter, H. C., Collison, A., Russo, R. C., Foot, J. S., Yow, T. T., Vieira, A. T., Tavares, L. D., Mattes, J., Teixeira, M. M., & Jarolimek, W. (2015) · Respiratory Research · doi:10.1186/s12931-015-0200-z · Cited by 61
Targeted Drug Delivery Using Immunoconjugates: Principles and Applications
Pasquetto, M. V., Vecchia, L., Covini, D., Digilio, R., & Scotti, C. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318234ecf5 · Cited by 61
Lata, J. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i24.2890 · Cited by 58
Pisani, A., Sabbatini, M., Riccio, E., et al. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0828-2 · Cited by 57
Marberger, H., Huber, W., Bartsch, G. C., Schulte, T., & Swoboda, P. (1974) · International Urology and Nephrology · doi:10.1007/bf02081999 · Cited by 56
Nannipieri, M., Cecchetti, F., Anselmino, M., Mancini, E., Marchetti, G., Bonotti, A., Baldi, S., Solito, B., Giannetti, M., Pinchera, A., et al. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9701-x · Cited by 53
OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease
Alkhouri, N., Berk, M. P., Yerian, L. M., López, R., Chung, Y. M., Zhang, R., McIntyre, T. M., Feldstein, A. E., & Hazen, S. L. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3031-8 · Cited by 52
Micro RNAs in the development of non-alcoholic fatty liver disease
Gerhard, G. S. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v7.i2.226 · Cited by 52
Borrelli, A., Schiattarella, A., Bonelli, P., Tuccillo, F. M., Buonaguro, F. M., & Mancini, A. (2014) · BioMed Research International · doi:10.1155/2014/476789 · Cited by 50
Self-citationPande, C., Kumar, A., & Sarin, S. K. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283537d61 · Cited by 47
Novel bile acid therapeutics for the treatment of chronic liver diseases
Hegade, V. S., Speight, A., Etherington, R. E., & Jones, D. E. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16630712 · Cited by 46
van Katwyk, S., Coyle, D., Cooper, C., Pussegoda, K., Cameron, C. G., Skidmore, B., Brener, S. S., Moher, D., & Thavorn, K. (2016) · Liver International · doi:10.1111/liv.13260 · Cited by 45
Kaneda, Y. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.510511 · Cited by 44
Pathways to Aging: The Mitochondrion at the Intersection of Biological and Psychosocial Sciences
Picard, M. A. (2011) · Journal of Aging Research · doi:10.4061/2011/814096 · Cited by 42
Advances in pharmacotherapy for primary biliary cirrhosis
Mousa, H. S., Lleò, A., Invernizzi, P., Bowlus, C. L., & Gershwin, M. E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.998650 · Cited by 40
Postformulation Peptide Drug Loading of Nanostructures
Pan, H., Marsh, J. N., Christenson, E. T., Soman, N. R., Ivashyna, O., Lanza, G. M., Schlesinger, P. H., & Wickline, S. A. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-391860-4.00002-1 · Cited by 39
Micelles from Amphiphilic Block Copolyphosphates for Drug Delivery
Zhai, X., Huang, W., Liu, J., Pang, Y., Zhu, X., Zhou, Y., & Yan, D. (2011) · Macromolecular Bioscience · doi:10.1002/mabi.201100163 · Cited by 38
Evogliptin: First Global Approval
McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0496-5 · Cited by 38
The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know
Pereira, K., Salsamendi, J. T., & Casillas, J. (2015) · Journal of Clinical Imaging Science · doi:10.4103/2156-7514.157860 · Cited by 33
Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions
Bourg, C. A., & Phillips, B. B. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q400 · Cited by 33
Molavi, B., Rassouli, N., Bagwe, S., et al. (2008) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 33
Kountouras, J., Boziki, M. K., Pοlyzos, S. A., Katsinelos, P., Gavalas, E., Zeglinas, C., Tzivras, D., Romiopoulos, I., Giorgakis, N., Anastasiadou, K., et al. (2017) · Free Radical Research · doi:10.1080/10715762.2016.1271122 · Cited by 31
The impact of bariatric surgery on nonalcoholic fatty liver disease
de Freitas, A. C. T., Campos, A. C. L., & Coelho, J. C. U. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282fbd33f · Cited by 29
The emerging problem of nonalcoholic steatohepatitis (NASH).
Portincasa, P., Grattagliano, I., Palmieri, V. O., & Palasciano, G. (2005) · PubMed · Cited by 28
Micro RNAs in the development of non-alcoholic fatty liverdisease
Glenn, Gerhard, Johanna, & DiStefano (2015) · World Journal of Hepatology · Cited by 28
Hide, D., Ortega‐Ribera, M., Fernández‐Iglesias, A., Fondevila, C., Salvadó, M. J., Arola, L., García‐Pagán, J. C., Mancini, A., Bosch, J., & Gracia‐Sancho, J. (2014) · Clinical Science · doi:10.1042/cs20140125 · Cited by 26
Self-citationEpidemiology of nonalcoholic fatty liver disease: A primer
Do, A., & Lim, J. K. (2016) · Clinical Liver Disease · doi:10.1002/cld.547 · Cited by 26
The role of gut microbiota in the pathogenesis of obesity
Żak‐Gołąb, A., Olszanecka‐Glinianowicz, M., Kocełak, P., & Chudek, J. T. (2014) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1086419 · Cited by 24
Soriano, G., Sánchez, E., Guarner, C., & Schiffrin, E. J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.019 · Cited by 22
Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash
Liles, J., Karnik, S. K., Hambruch, E., Kremoser, C., Birkel, M., Watkins, W. J., Tumas, D. B., Breckenridge, D. G., & French, D. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)01682-2 · Cited by 21
Retargeting adenoviral vectors to improve gene transfer into tumors
Hogg, R. T., Thorpe, P. E., & Gerard, R. D. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.78 · Cited by 17
Domann, F. E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048491 · Cited by 17
Cited by
The microbiota and microbiome in pancreatic cancer: more influential than expected
Wei, M.-Y., Shi, S., Liang, C., Meng, Q.-C., Hua, J., Zhang, Y.-Y., Liu, J., Zhang, B., Xu, J., & Yu, X.-J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1008-0 · Cited by 268
Gut microbiota dysbiosis in a cohort of patients with psoriasis
Hidalgo‐Cantabrana, C., Gómez, J., Delgado, S., Requena‐López, S., Queiro‐Silva, R., Margolles, A., Coto, E., Sánchez, B., & Coto‐Segura, P. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17931 · Cited by 236
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
Świderska, M., Maciejczyk, M., Zalewska, A., Pogorzelska, J., Flisiak, R., & Chabowski, A. (2019) · Free Radical Research · doi:10.1080/10715762.2019.1635691 · Cited by 107
Liu, Z., Zhou, X., Wang, W., Gu, L., Hu, C., Sun, H., Xu, C., Hou, J., & Jiang, Z. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07884 · Cited by 77
Metadata
- Authors
- Borrelli, A., Bonelli, P., Tuccillo, F. M., Goldfine, I. D., Evans, J. L., Buonaguro, F. M., & Mancini, A.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 15
- Pages
- 467-479
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W2794269010
- Cited by
- 266
- References
- 184
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.